Emergent BioSolutions Inc. EBS reported a first-quarter 2023 adjusted loss of $3.17 per share, wider than the Zacks Consensus Estimate of a loss of $1.67. The figure also missed our model estimate of ...
Fintel reports that on August 22, 2024, Rodman & Renshaw initiated coverage of Emergent BioSolutions (NYSE:EBS) with a Buy recommendation. As of August 6, 2024, the average one-year price target for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results